Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.